Nolvadex 10mg/tab 50 Tabletten by Beligas Pharmaceuticals

Usage

1. Calculate your start date by counting forward from the last administered dose by the half-life of the slowest-clearing compound in your cycle — for long-ester injectables, this is typically 14 days post-last-injection.
2. Take your daily Nolvadex dose in the morning with a small meal to minimise any gastrointestinal discomfort, swallowing tablets whole with a full glass of water.
3. During Weeks 1–2, administer 4 tablets (40 mg) daily, spacing the dose consistently each morning to maintain stable Tamoxifen plasma levels given the compound's five-to-seven-day active half-life.
4. Step down to 2 tablets (20 mg) daily from Week 3, then to 1 tablet (10 mg) in the final phase — the blister format lets you track daily compliance tablet by tablet.
5. Avoid concurrent use of potent CYP2D6 inhibitors (including certain antidepressants such as paroxetine and fluoxetine), as these reduce hepatic conversion of Tamoxifen to its more active metabolite, Endoxifen, and may blunt PCT effectiveness.
6. Order bloodwork at the conclusion of your PCT protocol — minimum panel: total testosterone, LH, FSH, and estradiol — to confirm HPG axis recovery before resuming normal training periodisation or considering a next cycle.

Warnings

Frequently asked questions

When exactly should I start Nolvadex PCT after finishing a steroid cycle?

Start Nolvadex PCT after the last administered compound has cleared its active half-life — typically 2 weeks after a long-ester injectable cycle (e.g., Testosterone Enanthate) or 24–48 hours after a short-ester or oral-only cycle. Beginning too early while androgens are still circulating blunts the SERM's effectiveness, since suppression is still being actively maintained by the exogenous hormone.

How long does a standard Tamoxifen-based PCT protocol last for natural testosterone recovery?

A standard Tamoxifen PCT runs four to six weeks, with clinical data supporting measurable LH and testosterone recovery within that window for most users. Heavier or longer cycles may require a six-week protocol or adjunct hCG use in the initial phase. Recovery status should always be confirmed through bloodwork — serum LH, FSH, and total testosterone — not assumed from time alone.

Is Nolvadex sufficient on its own for PCT, or does it need to be combined with other drugs?

Nolvadex is often sufficient as a standalone PCT agent for moderate cycles involving testosterone at typical performance doses. For prolonged, high-dose, or multi-compound cycles — particularly those involving 19-nor compounds like Nandrolone or Trenbolone — many practitioners pair Tamoxifen with hCG during the first two weeks to directly stimulate testicular Leydig cells before the SERM phase. Clomiphene is sometimes added for dual-receptor coverage, though this increases side-effect exposure.

Why is the 10 mg tablet the most practical dose format for a PCT taper?

The 10 mg per tablet format maps directly onto the standard PCT tapering schedule: 40 mg daily (4 tablets), 20 mg (2 tablets), and 10 mg (1 tablet) across descending weekly phases — all whole-tablet doses requiring no splitting or estimation. This precision matters because reducing SERM exposure gradually avoids rebound estrogen spikes as the HPG axis stabilises, and whole-tablet dosing eliminates the content variance introduced by cutting higher-strength tablets.

Are the Nolvadex tablets sold individually in strips or in a sealed container, and how does the packaging protect tablet integrity?

Beligas Pharmaceuticals packages Nolvadex in blister-format strips, which protect each tablet from moisture and oxidation individually — a meaningful advantage over loose jar packaging for a compound intended for a four-to-six-week administration window. Blister seals also support discretion and portability during a PCT cycle, and each tablet's sealed cavity maintains dose integrity until the point of use. (2) angle_used

Manufacturer

Beligas Pharmaceuticals entered the pharmaceutical-grade performance supplement market with a founding commitment that remains identifiable across its catalogue today: every product released under the Beligas name would carry independently verifiable analytical documentation rather than relying on label claims alone. For Nolvadex — a product where dosing precision is directly tied to the outcome of a multi-week hormonal recovery protocol — this founding principle takes on particular operational weight. The company's tablet manufacturing infrastructure supports lot-by-lot HPLC quantification as a release criterion, meaning the 10 mg Tamoxifen Citrate figure on the Nolvadex label reflects a chromatographically measured value confirmed against pharmacopoeial reference standards, not a calculation derived from raw-material input weights. Beligas built this verification infrastructure early in its development, recognising that the performance market's most informed users — those planning structured PCT after cycle completion — would eventually demand the same analytical accountability that clinical pharmaceutical channels take as standard. That decision has shaped the brand's reputation in a market segment where underdosed SERM tablets represent a concrete risk: if a PCT tablet delivers 7 mg instead of 10 mg, the entire protocol's gonadotropin-stimulating effect is proportionally compromised. The LAL (Limulus Amebocyte Lysate) endotoxin testing protocol applied at batch release adds a further safety layer specific to oral tablet manufacture. Across its years of operation, Beligas Pharmaceuticals has expanded its portfolio without diluting the QC standard that defined its initial market entry — Nolvadex sits within that framework as one of the most analytically straightforward products to verify, and the company's release data reflects that.